Peters Brian M, Luna-Tapia Arturo, Tournu Hélène, Rybak Jeffrey M, Rogers P David, Palmer Glen E
Department of Clinical Pharmacy, College of Pharmacy, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA.
Department of Oral and Craniofacial Biology, School of Dentistry, LSU Health Sciences Center, New Orleans, Louisiana, USA.
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00084-17. Print 2017 Jun.
We recently reported that a endosomal trafficking mutant continues to grow after treatment with the azole antifungals. Herein, we report that the Δ/Δ mutant does not have a survival advantage over wild-type isolates after fluconazole treatment in a mouse model of vaginal candidiasis. Furthermore, loss of does not synergize with established mechanisms of azole resistance, such as overexpression of efflux pumps or of Erg11p, the target enzyme of the azoles. In summary, although loss of function enhances survival after azole treatment , it does not seem to affect azole susceptibility .
我们最近报道，一种内体运输突变体在用唑类抗真菌药治疗后仍继续生长。在此，我们报告在阴道念珠菌病小鼠模型中，Δ/Δ突变体在氟康唑治疗后与野生型分离株相比没有生存优势。此外， 的缺失不会与已确立的唑类耐药机制协同作用，例如外排泵或唑类的靶酶Erg11p的过表达。总之，虽然 功能的缺失增强了唑类治疗后的 生存能力，但它似乎并不影响唑类敏感性。
